ZYME
Company Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 105.97M | 76.30M | 76.01M | 412.48M | 26.68M | 38.95M | 29.54M | 53.02M | 51.76M | 11.01M | 9.66M | 1.67M |
| Net Income | (81.13M) | (122.69M) | (118.67M) | 124.34M | (211.84M) | (180.55M) | (145.44M) | (36.56M) | (10.41M) | (33.81M) | (19.17M) | (12.94M) |
| EPS | -1.08 | -1.62 | -1.72 | 1.91 | -4.06 | -3.58 | -3.83 | -1.26 | -0.49 | -1.72 | -0.97 | -0.65 |
| Free Cash Flow | (34.53M) | (113.11M) | (122.38M) | 130.98M | (205.74M) | (157.67M) | (95.73M) | 20.76M | (2.90M) | (40.71M) | N/A | N/A |
| FCF / Share | -0.46 | -1.49 | -1.78 | 2.01 | -3.95 | -3.13 | -2.52 | 0.72 | -0.14 | -2.07 | N/A | N/A |
| Operating CF | (33.01M) | (110.04M) | (118.30M) | 144.11M | (192.45M) | (151.40M) | (81.85M) | 24.18M | 219,000 | (35.25M) | N/A | N/A |
| Total Assets | 346.53M | 463.09M | 580.88M | 648.73M | 389.13M | 538.38M | 368.20M | 244.36M | 131.96M | 94.00M | N/A | N/A |
| Total Debt | 18.27M | 18.51M | 26.72M | 28.11M | 32.33M | 8.64M | 6.93M | 57,000 | 62,000 | 4.42M | N/A | N/A |
| Cash & Equiv | 41.16M | 66.10M | 157.56M | 400.91M | 201.87M | 242.04M | 128.45M | 42.20M | 35.95M | 16.44M | N/A | N/A |
| Book Value | 268.50M | 338.77M | 464.81M | 492.96M | 249.09M | 409.92M | 245.68M | (145.27M) | 116.43M | 9.00M | N/A | N/A |
| Return on Equity | -0.30 | -0.36 | -0.26 | 0.25 | -0.85 | -0.44 | -0.59 | N/A | -0.09 | -3.76 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.41M | 2.52M | 27.61M | 48.73M | 27.11M | 31.03M | 16.00M | 19.24M | 10.03M | 16.93M | 16.51M | 7.00M |
| Net Income | (44.16M) | (41.21M) | (19.60M) | 2.32M | (22.64M) | (23.51M) | (29.85M) | (37.69M) | (31.65M) | (14.48M) | (28.69M) | (51.15M) |
| EPS | -0.59 | -0.55 | -0.26 | 0.03 | -0.30 | -0.31 | -0.39 | -0.49 | -0.42 | -0.20 | -0.41 | -0.76 |
| Free Cash Flow | (45.72B) | (10.55M) | (31.82M) | 11.19M | (3.75M) | (41.82M) | (6.87M) | (26.09M) | (38.33M) | 12.20M | (43.80M) | (7.20M) |
| FCF / Share | -612.28 | -0.14 | -0.42 | 0.15 | -0.05 | -0.55 | -0.09 | -0.34 | -0.50 | 0.17 | -0.63 | -0.11 |
| Operating CF | (45.72B) | (9.98M) | (31.41M) | 12.07M | (3.41M) | (41.51M) | (5.87M) | (24.99M) | (37.67M) | 13.95M | (42.67M) | (6.40M) |
| Total Assets | 478.21B | 346.53M | 397.27M | 408.38M | 425.52M | 463.09M | 487.15M | 515.63M | 553.75M | 580.88M | 556.37M | 602.05M |
| Total Debt | 17.04B | 18.27M | 18.90M | 18.68M | 18.46M | 18.51M | 20.25M | 20.06M | 25.22M | 26.72M | 26.37M | 27.25M |
| Cash & Equiv | 244.28B | 41.16M | 64.83M | 98.25M | 76.20M | 66.10M | 122.36M | 70.96M | 114.81M | 157.56M | 94.33M | 142.10M |
| Book Value | 163.59B | 268.50M | 320.06M | 334.51M | 324.97M | 338.77M | 366.98M | 406.16M | 438.00M | 464.81M | 424.34M | 448.92M |
| Return on Equity | -0.00 | -0.15 | -0.06 | 0.01 | -0.07 | -0.07 | -0.08 | -0.09 | -0.07 | -0.03 | -0.07 | -0.11 |
